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Abstract
 
Fibrosis and apoptosis are juxtaposed in pulmonary disorders such as asthma and the interstitial
diseases, and transforming growth factor (TGF)-
 
 
 
1 
 
has been implicated in the pathogenesis of
these responses. However, the in vivo effector functions of TGF-
 
 
 
1 
 
in the lung and its roles in
the pathogenesis of these responses are not completely understood. In addition, the relationships
between apoptosis and other TGF-
 
 
 
1
 
–induced responses have not been defined. To address
these issues, we targeted bioactive TGF-
 
 
 
1 
 
to the murine lung using a novel externally regulatable,
triple transgenic system. TGF-
 
 
 
1 
 
produced a transient wave of epithelial apoptosis that was
followed by mononuclear-rich inflammation, tissue fibrosis, myofibroblast and myocyte hyper-
plasia, and septal rupture with honeycombing. Studies of these mice highlighted the reversibility
of this fibrotic response. They also demonstrated that a null mutation of early growth response
gene (Egr)-1 or caspase inhibition blocked TGF-
 
 
 
1
 
–induced apoptosis. Interestingly, both inter-
ventions markedly ameliorated TGF-
 
 
 
1
 
–induced fibrosis and alveolar remodeling. These studies
illustrate the complex effects of TGF-
 
 
 
1 
 
in vivo and define the critical role of Egr-1 in the
TGF-
 
 
 
1 
 
phenotype. They also demonstrate that Egr-1–mediated apoptosis is a prerequisite for
TGF-
 
 
 
1
 
–induced fibrosis and remodeling.
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Introduction
 
Fibrosis is an important cause of morbidity and mortality in
a variety of lung diseases. This is nicely illustrated in
asthma, which is characterized by chronic inflammation
and subepithelial/airway fibrosis (1). It is also readily apparent
in the interstitial lung diseases (ILDs) including idiopathic
pulmonary fibrosis (IPF), scleroderma, and bleomycin lung
where pulmonary fibrosis is a dreaded and, in many cases,
fatal disease endpoint (2). In these disorders fibrosis often
coexists with structural cell apoptosis (3–7). Surprisingly,
the mechanisms of the fibrotic and apoptotic responses in
these lung disorders are poorly understood. In addition, the
relationship(s) between fibrosis and apoptosis has only been
superficially investigated. As a result, therapies that control
tissue fibrosis are not readily available and the usefulness of
apoptosis-based therapies as antifibrotic interventions has
not been adequately evaluated.
The “type II cytokine hypothesis of fibrosis” suggests
that fibrosis occurs in chronic inflammatory disorders when
cytokine balance shifts in a Th2 cell (type II) direction (8).
In accord with this hypothesis, IL-13 is believed to be the
key Th2 cell and fibrogenic effector in asthma (9, 10). IL-13
is also dysregulated in, and plays a critical role in, the
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 BAL, bronchoalveolar lavage; Egr, early
growth response gene; ICAD, inhibitor of caspase-activated DNase; IHC,
immunohistochemistry; ILD, interstitial lung disease; IPF, idiopathic pul-
monary fibrosis; PARP, poly(ADP)ribose polymerase; rtTA, reverse
tetracycline transactivator; tet-O, tetracycline operator; tTS, tetracycline-
controlled transcriptional silencer; TUNEL, TdT-mediated dUTP nick-
end labeling. 
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pathogenesis of many ILDs including IPF, scleroderma, ra-
diation-induced pulmonary fibrosis, and bleomycin lung
(11–15). Studies from our laboratory and others demon-
strated that IL-13 mediates its fibrotic effects via its ability
to induce and activate TGF-
 
 
 
1 
 
(16), and that TGF-
 
 
 
1 
 
is ex-
pressed in an exaggerated fashion and contributes to the
pathogenesis of asthma, the ILDs, and other fibrotic disor-
ders (16–23). Surprisingly, the degree to which TGF-
 
 
 
1
 
can account for the varied pathologies in these disorders
and the mechanism and reversibility of TGF-
 
 
 
1
 
–induced
fibrosis are poorly understood. In addition, our knowledge
of TGF-
 
  
 
effector pathways is limited and does not explain
how TGF-
 
 
 
1 
 
stimulates fibrosis while simultaneously in-
ducing structural cell apoptosis and tissue injury, and inhib-
iting epithelialization and wound healing (23–27). Lastly,
because TGF-
 
 
 
1
 
–induced fibrosis and apoptosis are consid-
ered distinct tissue responses, the role of apoptosis in TGF-
 
 
 
1
 
–induced fibrosis has not been defined.
To characterize the in vivo effector functions of TGF-
 
 
 
1 
 
and the mechanisms that mediate these responses, we
targeted biologically active TGF-
 
 
 
1 
 
to the human lung us-
ing the Clara cell 10-kD (CC10) protein promoter. To
bypass the fetal lethality that is seen when TGF-
 
 
 
1 
 
is ex-
pressed during lung development (28), we used a novel
triple transgenic system recently described by our labora-
tory (29). In these transgenic animals, TGF-
 
 
 
1 
 
produced a
striking pulmonary phenotype characterized by a transient
wave of epithelial apoptosis that is followed by mononu-
clear cell-rich tissue inflammation, subepithelial and pa-
renchymal fibrosis, myofibroblast and myocyte hyper-
plasia, and eventually, alveolar septal rupture and tissue
honeycombing. Studies of these mice highlighted the re-
versibility of TGF-
 
 
 
1
 
–induced fibrosis. They also demon-
strated that an intimate relationship exists between apopto-
sis and fibrosis because apoptosis was required for fibrosis
to be generated. Lastly, they highlight the importance of
the early growth response gene (Egr)-1 transcription factor
in mediating the apoptotic and fibrotic responses induced
by TGF-
 
 
 
1
 
.
 
Materials and Methods
 
Generation of the CC10-rtTA-tTS-TGF-
 
 
 
1 
 
Mice.
 
In virtually
all inducible overexpression transgenic systems, there is a low
level of transgenic protein production in the absence of the in-
ducing stimulus. This leak might be a problem in studies of the
effects of fetal lethal transgenes like TGF-
 
 
 
1 
 
and studies of the re-
versibility of transgene-induced tissue alterations. To address
these limitations, we developed a novel, triple transgenic system
that allows fetal lethal transgenes like TGF-
 
 
 
1 
 
to be expressed
(see Fig. 1). The first construct, CC10-rtTA-hGH, contains the
CC10 promoter, the reverse tetracycline transactivator (rtTA;
provided by M. Gossen and H. Bujard, Universität Heidelberg,
Heidelberg, Germany) and hGH intronic, nuclear localization,
and polyadenylation sequences. The second construct, tet-O-
CMV-hTGF-
 
 
 
1
 
-SV40, contains a polymeric tetracycline opera-
tor (tet-O), minimal CMV promoter, a modified TGF-
 
 
 
1 
 
cDNA
(provided by R. Derynck, University of California, San Fran-
cisco, San Francisco, CA), and SV40 intronic, polyadenylation,
and nuclear localization signals. In the TGF-
 
 
 
1 
 
cDNA construct,
the cysteine codons at positions 223 and 225 were replaced with
serine codons. This mutation prevents latency-associated protein
binding and gives rise to biologically active TGF-
 
 
 
1
 
. The third
construct, CC10-tTS-hGH, has the CC10 promoter driving the
expression of the tetracycline-controlled transcriptional silencer
(tTS). In this system, the CC10 promoter constitutively drives
the expression of rtTA and tTS in a lung-specific fashion. In the
absence of dox, tTS binds to and actively suppresses the expres-
sion of the tet-O–regulated TGF-
 
 
 
1 
 
transgene. In the presence of
dox, tTS is released allowing the activating, dox binding rtTA to
bind to the tet-O and activate transgene expression. To generate
these mice, the three constructs were generated, purified, and
pooled. Simultaneously pronuclear microinjection and character-
ization of the progeny were undertaken as described previously
by our laboratory (30). All founder and progeny animals were on
a C57BL/6 background.
 
Breeding to Egr-1 Null Mutant (Egr-1
 
   
 
) Mice.
 
CC10-rtTA-
tTS-TGF-
 
 
 
1 
 
animals were bred with wild-type and Egr-1 null
mutant (Egr-1
 
   
 
) animals as described previously by our labora-
tories (31). As a result of these crosses, CC10-rtTA-tTS-TGF-
 
 
 
1
 
animals with Egr-1
 
 
 
/
 
  
 
and Egr-1
 
    
 
loci were generated. The
phenotypes of these mice were compared as described below.
 
Dox Water Administration.
 
6–8-wk-old transgene
 
  
 
mice and
transgene
 
  
 
littermate controls were randomized to normal water
or water containing 0.5 mg/ml of dox as described previously
(29, 30). Transgene expression and phenotypic alterations were
evaluated at intervals thereafter.
 
Bronchoalveolar Lavage (BAL) and Quantification of TGF-
 
 
 
1 
 
Levels.
 
Mice were killed and BAL was undertaken as described previ-
ously (29, 30). The levels of TGF-
 
 
 
1 
 
were determined by ELISA
(R&D Systems) according to the manufacturer’s instructions.
 
TdT-mediated dUTP Nick-End Labeling (TUNEL) Evaluations.
 
End labeling of exposed 3
 
  
 
OH ends of DNA fragments was un-
dertaken with the TUNEL in situ cell death detection kit AP
(Roche Diagnostics) as described by the manufacturer. After
staining, 20 fields of alveoli were randomly chosen and 2,000 nu-
clei were counted. The labeled cells were expressed as a percent-
age of total nuclei.
 
Type II Alveolar Epithelial Cell Isolation and Apoptosis Evaluation.
 
Type II cells were isolated from wild-type and transgenic mice
using the methods developed by Rice et al. (32). After anesthesia,
the trachea was cannulated with 20-gauge tubing, the lungs were
filled with 2 ml dispase (Roche Diagnostics), followed by 0.5 ml
of 1% low melting point agarose. The agarose was allowed to
harden under crushed ice. The lungs were then placed in 2 ml
dispase for 1 h at room temperature, and transferred to DMEM
with 25 mM Hepes with 0.01% DNase I (Sigma-Aldrich). After
teasing apart the digested tissue, the resulting cell suspension was
sequentially filtered through nylon mesh filters and collected after
centrifugation for 8 min at 130 
 
g
 
. Contaminating cells were re-
moved by incubating the cell suspension in 100-mm tissue cul-
ture plates coated with a mixture of anti-CD16/CD32 and anti-
CD45 monoclonal antibodies (BD Biosciences) overnight at 4
 
 
 
C,
and washing the nonadherent cell population. In accord with the
literature, the resulting cells were 
 
 
 
97% type II cells and 
 
 
 
97%
viable as demonstrated by histochemical and immunohistochemi-
cal evaluations and trypan blue dye exclusion, respectively (32).
These cells were resuspended in 1
 
  
 
binding buffer at 10
 
6 
 
cells/ml
for subsequent FACS
 
® 
 
analysis. Annexin V and propidium iodine
staining were undertaken with the annexin V FITC apoptosis de-
tection kit (BD Biosciences). Analysis was undertaken by flow
cytometry (Becton Dickinson). 
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Histologic Analysis.
 
The lungs were removed en bloc, inflated
at 25 cm pressure with neutral buffered 10% formalin, fixed in
10% formalin, embedded in paraffin, sectioned, and stained. He-
matoxylin and eosin and Mallory’s trichrome stains were per-
formed in the Research Histology Laboratory of the Department
of Pathology at Yale University School of Medicine.
 
Collagen Assay.
 
Collagen content was determined biochemi-
cally using standard hydroxyproline assays or by quantifying total
soluble collagen using the Sircol Collagen Assay kit (Biocolor)
according to the manufacturer’s instructions. The data is ex-
pressed as the collagen content of the entire right lung.
 
mRNA Analysis.
 
mRNA levels were assessed using RT-
PCR assays and ribonuclease protection assays as described by our
laboratories (29, 30). In these assays, total cellular RNA from
lungs or other mouse tissues were obtained using trizol reagent
(GIBCO BRL) according to the manufacturer’s instructions.
 
Immunoblot Analysis.
 
Transgene
 
  
 
and transgene
 
  
 
mice were
randomized to normal water or dox at 6 wk of age and main-
tained on this regimen for 2 d. Lung lysates were then prepared
and Western analysis was undertaken with antibodies that reacted
selectively with caspase 3, caspase 7, caspase 8, poly(ADP)ribose
polymerase (PARP), 
 
 
 
-tubulin (Santa Cruz Biotechnology, Inc.),
BID (Cell Signaling Technology), cleavage site–specific BID
(Biosource International), 
 
 
 
II-spectrin (Chemicon), or inhibitor
of caspase-activated DNase (ICAD; Chemicon) as described pre-
viously (30).
 
Immunohistochemistry (IHC).
 
IHC was undertaken to localize
 
 
 
-smooth muscle actin (DakoCytomation), pro–SP-C (Chemi-
con), and 
 
 
 
-smooth muscle myosin heavy chain (Biomedical
Technology). These assays were undertaken as described previ-
ously by our laboratories (33).
 
Morphometric Analysis.
 
Alveolar remodeling was estimated
from the mean cord length of the airspace. This measurement is
similar to the mean linear intercept, a standard measure of air
space size, but has the advantage that it is independent of alveolar
septal thickness. These evaluations were performed as described
previously by our laboratory (30). In selected experiments, in-
flammation was also evaluated. In these evaluations peribronchial
cells were quantitated within a 4,000 
 
 
 
m
 
2 
 
area of the broncho-
vascular bundle as described previously (34).
Figure 1. Constructs involved in CC10-rtTA-tTS-
TGF- 1 mice and regulation of transgenic TGF- 1.
(A) The constructs that were used to make the transgenic
mice are illustrated. (B–E) Transgene  and transgene 
mice were randomized to normal or dox water for the
noted intervals (in B and D: h, hours; D, days; M,
month) or for 7 d (C and E). Whole lung TGF- 1
mRNA (B and C) and BAL TGF- 1 protein (D and E)
were assessed by RT-PCR and ELISA, respectively.
The lung specificity of transgene targeting was assessed
in F where RT-PCR was used to quantitate the levels
of TGF- 1 mRNA in the lungs and other organs from
transgene  mice on dox for 1 wk. The values in D and
E are the means   SEM of evaluations in a minimum
of five animals. The experiments in B, C, and F are
representative of four similar experiments. 
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Pharmacologic Interventions. 6–8-wk-old transgene  and trans-
gene  mice were randomized to the desired agent or the appro-
priate vehicle control. 2 d later, they were randomized to normal
or dox water and maintained on this regimen for 2 wk. At the
end of this interval, the animals were killed and pulmonary phe-
notype was assessed as described below. In experiments in which
caspase-mediated apoptosis was being evaluated, Z-VAD-fmk
was administered at a dose of 3 mg/kg/day via an i.p. route (Cal-
biochem). In experiments in which the selective inhibition of
caspases 3 and 7 was being evaluated, caspase 3/7 inhibitor
1 (5-[(s)-(-)-2-(methoxymethyl)pyrrolidine]sulfonylisatin; 4 mg/
kg/day, i.p.; Calbiochem) was used. In all cases, comparisons to
appropriate vehicle controls were undertaken.
Statistical Analysis. Values are expressed as means   SEM. As
appropriate, groups were compared by ANOVA with Scheffe’s
procedure posthoc analysis, with the Student’s two-tailed un-
paired t test or with nonparametric assessments (Wilcoxon’s Rank
Sum, Mann-Whitney U Test) using the software for the Macin-
tosh (Stat View; Abacus Concepts, Inc.).
Results
Generation of TGF- 1 Transgenic Mice. The constructs
that were required to generate these mice were prepared
and microinjected. Three triple transgene  founder mice
were identified and lines were established from each
by breeding with wild-type C57BL/6 animals. In the
transgene  progeny from these matings, all three transgenic
constructs were uniformly present and appropriate trans-
gene regulation was appreciated. In the absence of dox,
these mice did not express significant transgenic TGF- 1 in
lung RNA RT-PCR (35 cycles) assays or ELISA evalua-
tions of BAL fluids (Fig. 1, B–D). They did, however,
manifest significant inducibility with transgenic TGF- 1
being noted after 12 h and steady-state levels of BAL TGF-
 1 between 250 and 1,6000 pg/ml being appreciated after 1
wk of dox administration (Fig. 1, B–E, and not depicted).
These levels were maintained for the duration (up to 3 mo)
Figure 2. TGF- 1–induced apoptosis.
Transgene  and transgene  mice were
randomized to normal water (Dox ( ))
or dox water (Dox ( )). Lungs were
obtained 48 h (A and B) or at intervals
(C) thereafter and TUNEL (A and C) or
propidium iodide/annexin V staining and
FACS® (B) evaluations were undertaken.
A is shown at a magnification of 40.
(B) The top histograms illustrate the re-
sults with whole lung cells and the bottom
histograms show the results with isolated
alveolar type II cells. Using whole lung
RNA or lung lysates from animals 48 h
after randomization, ribonuclease pro-
tection was used to assess the expression
of caspases (D), and Western evaluations
were undertaken to evaluate caspase ac-
tivation and the levels of total and
cleaved BID (E, tBID). Western evalua-
tions of the cleavage of PARP and
ICAD and the kinetics of cleavage of
 II-spectrin are shown in F. (C) The
values represent the mean    SEM of
evaluations in five animals. (A and E–F)
A representative of a minimum of five
experiments is shown.Lee et al. 381
of dox administration and returned to undetectable levels
within 48 h of the removal of dox from the animals’ drink-
ing water (not depicted). In all cases TGF- 1 was success-
fully targeted to the lung because TGF- 1 mRNA could
not be appreciated in a variety of other tissues from these
animals (Fig. 1 F).
Phenotypic Analysis of Transgenic Mice. To define the ef-
fects of TGF- 1, 6-wk-old triple transgene positive (here-
after referred to as transgene ) animals and their transgene 
littermate controls were randomized to normal water or
dox water as described previously by our laboratory (30).
At intervals thereafter, animals were killed and their lungs
were analyzed. Qualitatively similar, dose-dependent phe-
notypes were appreciated in these mice with early apopto-
sis followed by inflammation, fibrosis,  -smooth muscle
actin  cell accumulation, and alveolar remodeling. Each
feature is described below.
TGF- 1–induced Apoptosis. After as little as 12 h of
TGF- 1 induction, a TUNEL  cell death response could
be readily appreciated in lungs from transgene  but not
transgene  animals (Fig. 2 A). The TUNEL  cells were
largely epithelial cells as evidenced by their histologic loca-
tion and double labeling experiments (Fig. 2 A and not de-
picted). Small numbers of TUNEL  macrophages could
also be appreciated. Propidium iodine and annexin V stain-
ing confirmed these findings. They also defined the nature
of this death response by demonstrating that TGF- 1 in-
creased the levels of apoptosis and combined apoptosis and
necrosis in whole lung cells and isolated type II alveolar ep-
ithelial cells (Fig. 2 B). This TUNEL  response peaked af-
ter 48 h of dox administration and disappeared despite con-
tinuous dox administration. It was no longer detectable
after 4–5 d of dox administration and did not reappear dur-
ing the 2-mo study interval (Fig. 2 C). During the apop-
totic phase, enhanced levels of mRNA encoding caspases 3,
7, 8, and 11, and impressive levels of caspase 7 and caspase
8 and lesser levels of caspase 3 activation, were appreciated
(Fig. 2, D and E, and not depicted). Western analysis also
revealed impressive cleavage of caspase targets including
PARP, ICAD, and  II spectrin, which were cleaved to
Figure 3. TGF- 1–induced inflam-
mation and fibrosis. Transgene   and
transgene   mice were randomized to
normal or dox water. BAL was under-
taken and tissues were obtained at intervals
thereafter. (A) Total BAL cell recovery is
illustrated. (B) We compare the histology
(hematoxylin and eosin staining, a mag-
nification of 40) of transgene   and
transgene  mice on dox water for 1 mo.
Accumulating macrophages (open arrow)
and eosinophils (closed arrow) are appreci-
ated. (C) Trichrome staining (a magnifi-
cation of 20) was used to compare the
collagen in lungs from transgene  and
transgene  mice on normal water and
transgene  mice on dox for up to 10 d
(left) and 1 mo (right). (D) Hydroxypro-
line assays were used to assess collagen
content. Transgene   mice on normal
water could not be differentiated from
transgene  mice on normal or dox water
in these assays. (A and D) The values rep-
resent the mean   SEM of evaluations in
a minimum of five animals. (B and C) A
representative of a minimum of five ex-
periments is shown.Erg-1 in TGF- 1–induced Apoptosis and Fibrosis 382
85-, 20-, and 110–115-kD fragments, respectively (Fig. 2
F). Control antisera did not reveal similar patterns (not de-
picted). Thus, TGF- 1 induces an early and transient wave
of epithelial apoptosis that is repressed and/or eliminated
with continuing TGF- 1 elaboration.
TGF- 1–induced Inflammation. Dox administration caused
a prominent inflammatory response in lungs from transgene 
animals but not their littermate controls. This effect could
be seen after as little as 2 d of transgene activation and in-
creased in intensity over the ensuing 10 d. In BAL, it man-
ifests as an increase in total cell and macrophage recovery
(Fig. 3 A and not depicted). In lung tissues, it was largely
due to an increase in macrophages (Fig. 3 B, open arrows).
However, a modest increase in eosinophils could also be
appreciated (Fig. 3 B, closed arrows).
TGF- 1–induced Fibrosis. The induction of TGF- 1 in
transgene  mice caused a readily apparent airway and pa-
renchymal fibrotic response when compared with transgene 
mice on normal or dox water and transgene  mice on nor-
mal water. On trichrome stains, this response could be
appreciated after as little as 2 d of dox administration, pre-
dominately in the subepithelial and adventitial regions of
the airway (Fig. 3 C). With longer periods of dox adminis-
tration, this fibrotic response could be appreciated in the al-
veolar parenchyma (Fig. 3 C). In accord with these find-
ings, lung collagen content continued to increase over the
2-mo period of dox administration (Fig. 3 D).
TGF- 1–induced Alveolar Remodeling. After prolonged
periods of dox administration, alveolar remodeling could
be readily appreciated in lungs from transgene  but not
transgene  mice. This response was patchy in nature and
associated with alveolar septal thickening and areas of septal
rupture. In many areas it had the appearance of honeycomb
lung (Fig. 4 A). This honeycombing caused increases in
chord length (the morphometric quantification of the dis-
tance between alveolar walls) that could be appreciated af-
ter 7 d of dox and were most prominent with longer peri-
ods of TGF- 1 elaboration (Fig. 4 B).
TGF- 1–induced  -smooth Muscle Actin Accumulation. To
determine if TGF- 1 caused alterations in myocytes and or
myofibroblasts,  -smooth muscle actin IHC was under-
taken. When compared with lungs from transgene  mice
on normal or dox water and transgene  mice on normal
water, 10 d of dox administration caused a prominent
increase in  -smooth muscle actin  cells in lungs from
transgene  animals (Fig. 5). Many of these cells were also
 -smooth muscle myosin heavy chain  and were located in
smooth muscle bundles (Fig. 5). However, many were not
in smooth muscle bundles and did not stain with myosin
heavy chain (Fig. 5). Thus, the increase in smooth muscle
Figure 4. TGF- 1–induced alveolar remodeling. Trans-
gene  and transgene  mice were randomized to normal or
dox water. Their lungs were obtained and fixed to pressure at
intervals thereafter. (A) We compare (trichrome) lungs
from transgene  and transgene  mice on dox for 1 mo (a
magnification of 20). (B) Morphometric assessments of
chord length are compared. Transgene  mice on dox water
and transgene  mice on normal water could not be differ-
entiated from transgene  mice on normal water in these
assays. (A) A representative of a minimum of five experi-
ments is shown. (B) The values represent the mean  
SEM of evaluations in a minimum of five animals.
Figure 5. TGF- 1–induced myocyte and myofibroblast alterations.
Transgene  and transgene  mice were randomized to normal or dox water
and lungs were evaluated 1 mo later. (A) On the top, IHC assessments of
 -smooth muscle actin were undertaken. The closed arrows highlight
peribronchial positive cells and the open arrows highlight positive cells a
distance from the airway. On the bottom, IHC assessments of smooth
muscle myosin heavy chain are compared. The arrows highlight the staining
cells in the smooth muscle bundle. All photos are at a magnification of 15.
(B) Trichrome staining is used to compare airways from transgene  and
transgene  mice on dox for 1 mo (shown at a magnification of 15). The
arrow highlights the enlarged smooth muscle bundle. Transgene  mice on
dox water and transgene  mice on normal water could not be differentiated
from transgene  mice on normal water in these assays. (A and B) A repre-
sentative of a minimum of five experiments is shown.Lee et al. 383
actin staining cells is due, at least in part, to an increase in
myocytes and myofibroblasts (Fig. 5).
Role of Egr-1. We hypothesized that Egr-1 might play
an important role in the pathogenesis of the TGF- 1 phe-
notype. To test this hypothesis, we first evaluated the ex-
pression of Egr-1 in our transgenic system. As noted in Fig.
6 A, Egr-1 was potently induced in lungs from dox-treated
transgene  animals but not transgene  controls. Interest-
ingly, Egr-2 and Egr-3 were also induced, whereas the
Egr-1 binding proteins NAB-1 and NAB-2 were not al-
tered. The role of Egr-1 was then defined by breeding
Egr-1    mice (31) and the TGF- 1 transgenic animals.
This allowed us to compare the phenotypes induced by
TGF- 1 in mice with wild-type (Egr-1 / ) and null mu-
tant (Egr-1   ) Egr-1 loci. The lungs from wild-type mice
and transgene /Egr-1    mice on normal or dox water
were virtually identical. In contrast, the TGF- 1 pheno-
type was markedly altered in Egr-1    animals. In the ab-
sence of Egr-1, the early wave of apoptosis that was
induced by TGF- 1 was no longer appreciated. This dif-
ference was most prominent after 48 h of dox, where
21.3   3% of the nuclei in the lungs of transgene /Egr-
1    mice were TUNEL  versus no detectable staining in
transgene /Egr-1    animals (P   0.001; Fig. 6 B). In the
absence of Egr-1, TGF- 1–induced fibrosis was also mark-
edly ameliorated. This was seen in trichrome evaluations
(Fig. 6 C) and measurements of collagen content (Fig. 6 D;
*, P   0.01). Egr-1 deficiency also diminished TGF- 1–
induced alveolar remodeling, which was readily apparent
in histologic and with chord length evaluations (Fig. 6 E
and not depicted; *, P   0.01). Interestingly, TGF- 1–
induced BAL inflammation was not altered but parenchy-
mal inflammatory cell accumulation was modestly de-
creased in the absence of Egr-1 (Fig. 6, F and G). These
studies demonstrate that Egr-1 is a critical mediator of key
aspects of the in vivo TGF- 1 phenotype.
Figure 6. Regulation of Egr-1 and its role in TGF- 1–
induced apoptosis, fibrosis, remodeling, and inflammation.
Transgene  and transgene  mice with wild-type ( / )
and null mutant (   ) Egr-1 loci were randomized to
normal or dox water. After 48 h of dox, the levels of
mRNA encoding Egr transcription factors and binding
proteins (A) and the levels of apoptosis (B) were evaluated
with RT-PCR and TUNEL evaluations, respectively. After
10 d of dox administration, collagen content was evaluated
with trichrome evaluations (C, shown at a magnification of
10) and Sircol assays (D) and inflammation was evaluated
using BAL (F) and quantitative morphometry (G). Alveolar
remodeling (chord length) was evaluated after 1 mo of dox
(E, *, P   0.01). (A–C) A representative of a minimum of
five experiments is shown. (D–G) The values represent the
mean   SEM of evaluations in a minimum of five animals.Erg-1 in TGF- 1–induced Apoptosis and Fibrosis 384
Role of Apoptosis in TGF- 1–induced Fibrosis. Our stud-
ies with Egr-1 null mutant mice demonstrated that an in-
tervention that diminished TGF- 1–induced apoptosis also
decreased the ability of TGF- 1 to induce fibrosis and alve-
olar remodeling. This led to the hypothesis that there is an
intimate relationship between the apoptosis and the fibrotic
and remodeling phenotypes with the apoptosis being re-
quired to allow the latter phenotypes to be seen. To address
this hypothesis, experiments were undertaken in which
apoptosis was blocked via an Egr-1–independent mecha-
nism and the effects of this intervention on fibrosis and al-
veolar remodeling were assessed. In these experiments,
transgene  and transgene  mice were randomized to re-
ceive Z-VAD-fmk (3 mg/kg/day, i.p.) or vehicle control
starting 24 h before the dox. Z-VAD-fmk was a potent in-
hibitor of TGF- 1–induced apoptosis. In lungs from
transgene  mice on dox for 48 h, 17.8   2.5% of the cells
in the vehicle control–treated lungs were TUNEL  versus
no detectable staining in the Z-VAD-fmk–treated lungs
(P   0.01). Interestingly, Z-VAD-fmk inhibition of apoptosis
was also associated with a marked decrease in tissue fibrosis
on trichrome (Fig. 7 A) and total lung collagen (Fig. 7 B; *,
P   0.01) evaluations. Z-VAD-fmk treatment also amelio-
rated TGF- 1–induced alveolar remodeling (Fig. 7 C; *,
P   0.01). Similar results were noted in mice treated with a
selective caspase 3/7 inhibitor (not depicted). Interestingly,
Z-VAD-fmk did not alter TGF- 1–induced fibrosis when
it was administered 5 d after the initiation of dox (a time
point when TUNEL  cells are not longer appreciated; Fig.
6 D). Thus, in accord with what was noted with Egr-1 null
mutant animals, interventions that blocked apoptosis simul-
taneously decreased fibrosis and alveolar destruction. When
viewed in combination, these studies support the hypothe-
sis that TGF- 1–induced apoptosis is a critical early event
in the pathogenesis of TGF- 1–induced fibrosis and alveo-
lar destruction.
Reversibility of TGF- 1–induced Fibrosis. The reversibil-
ity of tissue fibrosis has critical consequences for the natural
history of fibrotic disorders. Unfortunately, the reversibility
of pulmonary fibrosis has not been adequately assessed and
what is known engenders controversy (35–37). A unique
feature of our transgenic system is the clarity with which it
allows the reversibility of tissue phenotypes to be evaluated.
To characterize the reversibility of TGF- 1–induced fibro-
sis, transgene  and transgene  mice were randomized to
normal or dox water for 10 d. At the end of this interval,
one group was analyzed while the other was placed on nor-
mal water and evaluated at intervals thereafter. As noted
above, dox caused an impressive increase in tissue fibrosis
in transgene  mice. Interestingly, after 1 mo on normal wa-
ter, this parenchymal fibrotic response had almost com-
pletely resolved. This was readily apparent in histologic and
collagen content evaluations (Fig. 8). These studies demon-
strate that the parenchymal fibrotic response that is induced
by TGF- 1 is reversible over time.
Discussion
TGF- 1 family proteins are multifunctional cytokines
that have been implicated in the pathogenesis of diverse bi-
ologic processes including cell growth and survival, cell and
tissue differentiation, development, inflammation, immu-
nity, hematopoiesis, and tissue remodeling and repair. On
superficial analysis, TGF- 1 can be accurately described as a
healing molecule that manifests impressive antiinflamma-
tory and fibrotic effects. On closer analysis, it is clear that
this perspective is only partially correct and that the effector
profile of TGF- 1 can appear confusing and even contra-
dictory (23, 25, 38, 39). This is impressively noted in the
setting of inflammation where TGF- 1 has important anti-
inflammatory and immunosuppressive effects in some set-
tings and proinflammatory effects in others (38, 40, 41).
Figure 7. Role of apoptosis in
TGF- 1–induced fibrosis and
remodeling. Transgene   and
transgene  mice were randomized
to normal or dox water. After 10 d
of dox, collagen content was
evaluated with trichrome evalua-
tions (A) and Sircol assays (B), and
alveolar remodeling was assessed
with chord length determinations
(C). (A–C) Z-VAD-fmk or its
vehicle control (Z-VAD-fmk
( )) was administered starting the
day before the dox. (D) Z-VAD-
fmk or its control was adminis-
tered 5 d after the initiation of
dox (*, P   0.01) and collagen
accumulation was assessed. (A) A
representative of a minimum of
five experiments is shown. (B–D)
The values represent the mean  
SEM of evaluations in a mini-
mum of five animals.Lee et al. 385
This is also seen in oncogenesis where TGF- 1 exerts
growth inhibitory effects on tumor cells while enhancing
tumor cell migration and invasion (39). Particularly rele-
vant to the present proposal, are studies that demonstrate
that, in the proper setting, TGF- 1 is essential for wound
healing, stimulates matrix molecule deposition and angio-
genesis, and is an essential mediator of the pathologic scar-
ing in fibrotic disorders (16, 22, 38, 42, 43). On the other
hand, TGF- 1 can also induce tissue injury (44) and cellu-
lar apoptosis, decrease epithelialization, and inhibit wound
healing (23–27). The complexity of these responses can be
attributed to a number of items including the state of acti-
vation and differentiation of the target cell, the presence of
other stimuli in the local microenvironment, and the ability
of TGF- 1 to exert its seemingly antagonistic effects via
different effector pathways (23, 25). The “contradictory”
nature of these responses also reflects an inadequate under-
standing of the mechanisms that TGF- 1 uses to induce its
complex tissue phenotypes. This is due, in part, to the lack
of experimental systems in which the acute and chronic ef-
fects of TGF- 1 can be characterized and their interrela-
tionships can be investigated in vivo. It is also due to the as-
sumption that each phenotype is a distinct endpoint in its
own right. The possibility that TGF- 1 may induce one
phenotype only if it induces an earlier “different” pheno-
type has not been considered. As a result, the relationships
between endpoints such as apoptosis and fibrosis have not
been investigated. To address these deficiencies, we gener-
ated and used a novel triple transgenic system that bypasses
the fatal lethal effects of TGF- 1 (28). With this system, we
demonstrated that transgenic TGF- 1 induces a complex
pulmonary phenotype with a transient wave of epithelial
apoptosis followed by inflammation, airway and parenchy-
mal fibrosis, myocyte and myofibroblast hyperplasia, and
alveolar remodeling. Experiments with these mice defined
target genes that mediate these complex responses by high-
lighting the central role that Egr-1 plays in the TGF- 1
response. They also illustrate the intimate relationship be-
tween apoptosis and fibrosis because three different inter-
ventions that blocked apoptosis also ameliorated the TGF-
 1–induced fibrotic response. This suggests that TGF- 1
simultaneously induces injury (apoptosis) and stimulates
fibrosis, and that the injury is required for the fibrosis to
occur.
In in vitro studies, TGF- 1 induces apoptosis in a variety
of cells including epithelial cells, T cells, and tumor cells
(45–47). This apoptosis and TGF- –mediated growth in-
hibition can be correlated with the tumor suppressive ef-
fects of TGF- 1 (45). Apoptosis is also believed to play an
important role in normal wound healing because TUNEL
staining cells localize in granulation tissue beneath the ad-
vancing epithelial edge of dermal wounds (45), and phago-
cytic cells produce TGF-  after ingesting apoptotic bodies
(48). However, the role of TGF- 1 in this apoptotic re-
sponse has not been defined. In addition, little else is
known about the importance of apoptosis in the generation
of other TGF-  responses. To define the role of apoptosis
in the pathogenesis of the TGF- 1 tissue phenotype, we
compared the kinetics of induction of the different TGF- 1
responses and the phenotypes induced by transgenic TGF-
 1 when apoptosis was inhibited or proceeding normally.
These studies demonstrated that a transient wave of TGF-
 1–induced apoptosis proceeds TGF- 1–induced tissue fi-
brosis, and that three different interventions that block this
apoptosis (Egr-1 null mutation, Z-VAD-fmk treatment,
and selective caspase 3/7 inhibition) markedly ameliorated
this fibrotic response. This demonstrates, for the first time,
that apoptosis precedes and is an essential prerequisite for
TGF- 1–induced fibrosis. These findings have impressive
implications. First, they suggest that the apoptosis at the ad-
vancing edge of wounds is required for a normal healing
response to occur. Second, they suggest that genetic or ac-
quired alterations in the intensity and/or kinetics of TGF-
 1–induced apoptosis can contribute to the severity, rate
Figure 8. Reversibility of TGF- 1–induced fibrosis.
Transgene  and transgene  mice were given normal or
dox water for 10 d. A subgroup of animals were then killed
and evaluated, and the others were placed on normal water
for 30 d. (A) Trichrome evaluations were used to compare
transgene  mice on normal water (a), transgene  mice on
dox for 10 d (b), and transgene  mice on dox for 10 d and
on normal water for 30 d (c; shown at a magnification of
15). Collagen content under these conditions is evaluated
in B. (A) A representative of a minimum of five experi-
ments is shown. (B) The values represent the mean  
SEM of evaluations in a minimum of five animals (*, P  
0.01 vs. transgene  on dox for 10 d only).Erg-1 in TGF- 1–induced Apoptosis and Fibrosis 386
of progression, and/or reversibility of fibrotic responses.
Lastly, because TGF- 1, apoptosis, and fibrosis often coex-
ist in diseases like asthma and the ILD (1–4, 6, 7, 17–21,
49), they suggest that interventions that alter apoptosis
might be therapeutically useful in controlling tissue fibrosis
in these disorders.
Our studies demonstrate that inhibition of apoptosis only
ameliorates fibrosis when the therapy is applied during a
critical temporal window early in the pathogenesis of a
TGF- 1 tissue response. This finding has important impli-
cations regarding the potential usefulness of this sort of an
intervention in preventing the progression of pathologic fi-
brosis. In diseases in which fibrosis is caused by a single in-
sult with a single wave of TGF- 1, interventions that block
early responses such as apoptosis would be expected to
ameliorate fibrosis only when given early on or in a pro-
phylactic fashion. In contrast, fibrosis can be caused by
multiple temporally dissociated injuries, each of which
causes its own wave of TGF- 1 elaboration. In this sce-
nario, multiple initiation/apoptosis events occur and the
clinical impression of disease progression is the result of the
sum of each of these discrete injury and repair responses. In
this setting, an intervention that blocks apoptosis can block
disease initiation or the progression of ongoing disease. In-
terestingly, there is mounting evidence that multiple tem-
porally discrete injuries contribute to the pathogenesis of
diseases such as IPF, asthma, and wound healing. This is
nicely illustrated in the exacerbations and remissions that
characterize asthma and the ability of apoptotic cells to
move with the leading edge of a healing wound (45). It is
also seen in IPF, the histology of which is characterized by
geographically discrete sites of injury that appear to be at
different stages of evolution and the ready appreciation of
apoptotic cells (5–7, 50). As a result, we believe apoptosis-
based inhibitors can be effective in preventing fibrotic pro-
gression in these and other human disorders. Additional ex-
perimentation will be needed to test these assumptions.
Egr-1 is an 80–82-kD inducible zinc finger transcription
factor that has also been identified as nerve growth factor–
induced A, Krox-24, ZIF-268, ETR-103, and TIS-8 (51–
53). It is the prototype of the Egr family that includes Egr-1,
Egr-2, Egr-3, Egr-4, and the Wilms’ tumor product.
Members of this family have been implicated in commit-
ments to proliferation, differentiation, and the activation of
cell death pathways. Egr-1 can be induced, both acutely
and chronically, at sites of injury and repair by a variety of
stimuli including cytokines, oxidized lipids, angiotensin II,
H2O2, and mechanical injury (51–55). It mediates its effects
by regulating the transcription of a wide array of down-
stream genes involved in inflammation, matrix formation,
thrombosis, and remodeling. Prominent targets include the
A and B chains of PDGF, fibroblast growth factor 2, vascu-
lar endothelial growth factor, CD44, tissue factor, fibro-
nectin, matrix metalloproteinases, plasminogen activator
inhibitor 1, and urinary plasminogen activator (51–53). In
accord with its ability to stimulate TNF, Fas, Fas L, PTEN
(a proapoptotic Egr-1 target), and p53, Egr-1 is also a potent
stimulator of cellular apoptosis in vitro (56, 57). Egr-1 can
stimulate TGF- 1 production, be stimulated by TGF- 1,
and inhibit TGF- RII expression in vitro (58–61). Our
studies demonstrate that TGF- 1 stimulates Egr-1 in vivo
and that Egr-1 is a central mediator of TGF- 1–induced
apoptosis, fibrosis, and alveolar remodeling in vivo. These
observations suggest that therapeutic interventions that
control Egr-1 activation or effector pathway initiation can
be therapeutically useful in controlling pathologic TGF- 1
responses. This can be accomplished a variety of ways be-
cause Egr-1 is activated via a complex process that involves
Egr-1 phosphorylation, Egr-1 specificity protein 1 binding,
and competition between Egr-1 and specificity protein 1
for GC-rich cis elements in the promoters of target genes
(62). These findings also have impressive implications for
diseases like pulmonary emphysema, which is characterized
by structural cell apoptosis, abnormal scarring, TGF- 1 in-
duction, and Egr-1 activation (63–65). In these diseases, it
is tempting to speculate that TGF- 1–induced Egr-1 acti-
vation is responsible for the apoptosis, fibrosis, and alveolar
destruction in this disorder.
It is commonly stated that fibrosis in the lung is irrevers-
ible (35, 36). This perception is derived from the relentlessly
progressive nature of diseases like IPF and from the progres-
sive fibrosis that has been described after high dose virally
mediated gene transfer with cytokines such as IL-1  and
TGF-  (66, 67). In contrast, there is a substantial body of
evidence in humans and modeling systems that fibrosis, in
some settings, can regress over time. This has been most in-
tensely studied in the liver where reversibility is seen in
modeling systems and cirrhotic humans after adequate ther-
apy for viral hepatitis (37, 68). Reversibility has also been
reported in patients with isocyanate asthma after cessation of
exposure (69) and in ILD modeling systems using low dose
adenovirus-mediated TGF- 1 gene transfer (70). Our stud-
ies demonstrate that transgenic TGF- 1 causes a parenchy-
mal fibrotic response that is largely reversible after the cessa-
tion of transgene expression. On superficial analysis, these
results would appear to differ significantly from the findings
that were obtained by Sime et al. (66) using high dose ade-
novirus gene transfer of TGF- 1. These differences could
accurately reflect the existence of irreversible and reversible
pulmonary fibrotic responses (68). Alternatively, the differ-
ences might be more technical than real because (a) the ade-
novirus system itself can cause significant lung injury; (b) the
high dose adenovirus system engendered levels of BAL
TGF- 1 as high as 90 ng/ml, which is  60-fold greater
than the physiologic levels seen in our system; and (c) the
adenovirus TGF- 1–treated mice were not observed for a
significant interval after their peak level of tissue fibrosis,
making it impossible to determine if resolution would have
occurred with longer periods of evaluation. Regardless, it is
clear from our studies that pulmonary fibrosis can resolve
over time. Additional experimentation will be required to
determine if this reversibility is still seen with higher, longer,
or repeated doses of TGF- 1. Additional experimentation
will also be required to test the exciting hypothesis sug-Lee et al. 387
gested by our apoptosis studies: the degree of reversibility of
a TGF- 1–induced fibrotic response in the lung is deter-
mined, at least in part, by the chronicity and/or severity of
the preceding epithelial apoptosis.
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